Conatus Pharmaceuticals Inc (CNAT) News

My guess is merger will happen. Vote expected on May 7th ... https://www.otcmarkets.com/filing/html?id=14112909&guid=IABHUqztWEfo2yh
LOGO
May 1, 2020
URGENT – PLEASE VOTE YOUR SHARES TODAY
Dear Fellow Shareholder,
I am writing to remind you that the Special Meeting of Conatus Pharmaceuticals Inc. (“Conatus”) to approve the merger with Histogen Inc. and related matters is scheduled for May 7, 2020.
Your vote is important, regardless of the number of shares you own. Please take a moment to vote your shares via the Internet, telephone OR sign, date and return the enclosed form of proxy, at your earliest convenience. Please note that voting by telephone or on the Internet will require that you have your proxy control number available. That number is printed on the enclosed form of proxy, or in an email if you elected to receive proxy materials electronically. Voting promptly will help reduce solicitation costs and eliminate the need for follow-up phone calls or mailings.
Your Board of Directors urges you to vote “FOR” all proposals.
FAILURE TO RETURN YOUR FORM OF PROXY OR A VOTE VIA THE INTERNET OR TELEPHONE MAY RESULT IN THERE NOT BEING A QUORUM PRESENT, THUS PREVENTING THE MEETING FROM OCCURRING.
PLEASE TAKE THE TIME TO VOTE TODAY.
If you have any questions or require assistance in voting your shares, please call Conatus’ proxy solicitor, Laurel Hill Advisory Group, LLC (“Laurel Hill”), at 1-888-742-1305.
You may receive a call asking you to exercise your right to vote. Laurel Hill has been retained by Conatus to make follow-up phone calls to help secure the remaining votes needed for the Special Meeting.
Thank you for taking time to vote and for your continued interest in Conatus.
Very truly yours,

LOGO
Steven J. Mento, Ph.D.
President and Chief Executive Officer


If you need assistance in voting your shares, please call our proxy solicitor, Laurel Hill Advisory Group, at 1-888-742-1305.

* * $CNAT Video Chart 05-05-2020 * *

Link to Video - click here to watch the technical chart video

What’s going on what’s the float

PM: $0.4190? WTF!

Long $0.52

1.00+

???translate to what , I have as many brain cells as a rock,.

The exchange ratio used to determine the number of shares of Conatus common stock issuable to Histogen stockholders pursuant to the merger was determined using a pre-transaction valuation of $100 million for Histogen’s business, based on its latest priced investment round and clinical pipeline advancement, and $35.135 million for Conatus’ business, an approximately 155% premium to the 20-day volume weighted average closing share price of Conatus prior to the signing date on the Nasdaq Capital Marke

????????? What size is the R/S,,,,,,,,,,,!

Big run a comin!

I say 0% just because the company has absolutely nothing going for it at this point. Maintaining some sort of listing compliance is just additional unnecessary expense. They should buy a fork to stick in the company.

If they do it's probably a precursor to issuing more shares.

What are the chances of a RS here? Been bit before on these low prices trying to become compliant

See it's happening!!

That would be nice! Do you base that opinion on any actual objective facts or evidence?

It'll start to uptrend soon. Hit bottom and gonna bounce!

Care to explain?

Gonna blow up soon!!

They still have alot of cash on hand

* * $CNAT Video Chart 09-11-2019 * *

Link to Video - click here to watch the technical chart video

Why volume? Why price?

* * $CNAT Video Chart 08-30-2019 * *

Link to Video - click here to watch the technical chart video

* * $CNAT Video Chart 07-11-2019 * *

Link to Video - click here to watch the technical chart video

any news or catalyst +27% hod .469

CNAT

long

Haven’t bought in yet. Waiting to see signs of life. Bounce is coming eventually

Here, dead kitty kitty kitty!

* * $CNAT Video Chart 07-03-2019 * *

Link to Video - click here to watch the technical chart video

bounce coming

CNAT smashed like GNAT.

the last nail in the coffin of this dog.

Disaster strikes: #msg-149568025.

Lol

Thank you kiss of death

Research on CNAT and their ability to scale the Nash opportunity https://msmoneymoves.com/2019/05/22/a-high-risk-high-reward-biotech-stock-targeting-nash-cirrhosis/

Slow creep upwards...

News: $CNAT Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis

SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication 1 in Hepatology Communications detailing results following seven-day treatment with emricasan, the company’s first-in-class pan-caspase inhibitor, in rats...

Find out more https://marketwirenews.com/news-releases/conatus-pharmaceuticals-announces-publication-demonstrating-that-emricasan-ameliorates-portal-hypertension-improves-liver-structure-and-function-in-a-preclinical-model-of-advanced-cirrhosis-8082678.html

$CNAT $.25 coming Fiscal Year Ends Dec 30, 2018
Most Recent Quarter (mrq) Dec 30, 2018
Profitability
Profit Margin -53.62%
Operating Margin (ttm) -54.42%
Management Effectiveness
Return on Assets (ttm) -17.47%
Return on Equity (ttm) -65.02%

* * $CNAT Video Chart 04-18-2019 * *

Link to Video - click here to watch the technical chart video

Look at the link, best of EASL 2019, what company is chosen

https://ilc-congress.eu/wp-content/uploads/2019/04/Best-of-ILC2019_Cirrhosis-and-complications-v1.0-190413.pptx

Why?

Thumbs up ?

you sure?
=========
The scientific community it’s giving a thumbs up! Any small improvement is a progress

Out of hundreds of companies presenting and 2800 poster presentations, Emricasan emerged as one of the best developments in EASL.

This should’ve gone up not down.


https://ilc-congress.eu/wp-content/uploads/2019/04/Best-of-ILC2019_Cirrhosis-and-complications-v1.0-190413.pptx

If you look at all the summary slides even where change was not significant it was still in the right direction and meaningful. The drug works and is worth something.

From EASL 2019
https://ilc-congress.eu/congress-news/ilc-daily-news-saturday-recap/
“In the ENCORE-PH Phase 2b trial in patients with NASH-related compensated cirrhosis with severe portal hypertension, treatment with oral pan-caspase inhibitor emricasan showed a trend toward greater change from baseline in hepatic venous pressure gradient (HPVG: primary endpoint) and clinically meaningful HPVG reduction in patients with very high baseline HPVG (≥16 mmHg).”

* * $CNAT Video Chart 04-15-2019 * *

Link to Video - click here to watch the technical chart video

I dunno but market over reacted to this for sure

In 2016, few months after Tobira failed to meet the primary endpoint for its NASH trial, was purchased for 1.7 billion by Allergan. Just because they miss the primary endpoint doesn’t mean that it is a complete failure. They look for other parameters.

The fact that it was accepted as a late breaking oral presentation was worthy of PR. Also, of importance was the fact that it was selected by EASL for inclusion in the “Best of ILC” summary slide deck highlighting the most noteworthy contributions to the scientific program at this year’s meeting. But what do they know?

It was previously announced Dec 5, 2018. The headlines and stuff today were the very definition of FAKE NEWS. All the Saturday presentation had was a bit more depth to the data but all the big conclusions were the same as on Dec 5th. Crazy

Its four month old data. They missed the endpoint four months ago.
Waiting for 48 week data still.